NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

Stock Information for NervGen Pharma Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NervGen Pharma Corp.

NervGen Pharma Announces Proposed Amendment to Warrants
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.